Additionally, anti-CCN2 antibodies may be applicable in other diseases such as cancer; pamrevlumab was shown to inhibit pro-tumour growth cross-talk between carcinoma cells and hepatic stellate cells (Makino et al., 2018). This evidence concerns the gene CCN2 and carcinoma.